Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial.
Ojeda Gonzalez B, Gonzalez Martin A, Bover Barcelo I, Fabregat i Mayol X, Mellado B, Rubio Perez MJ, Alonso Carrion L, Casado Herraez A, Calvo Garcia E, Churruca Galaz C, Arcusa Lanza A, Herrero Ibañez A, Adrover Cebrian E, Poveda Velasco A. Ojeda Gonzalez B, et al. Among authors: casado herraez a. Am J Clin Oncol. 2008 Oct;31(5):481-7. doi: 10.1097/COC.0b013e31816d1c7b. Am J Clin Oncol. 2008. PMID: 18838886 Clinical Trial.
Treatment guidelines in ovarian cancer.
Poveda Velasco A, Casado Herráez A, Cervantes Ruipérez A, Gallardo Rincón D, García García E, González Martín A, López García G, Mendiola Fernández C, Ojeda González B; GEICO Group. Poveda Velasco A, et al. Among authors: casado herraez a. Clin Transl Oncol. 2007 May;9(5):308-16. doi: 10.1007/s12094-007-0058-8. Clin Transl Oncol. 2007. PMID: 17525041
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators. Gonzalez-Martin A, et al. Eur J Cancer. 2013 Dec;49(18):3831-8. doi: 10.1016/j.ejca.2013.08.002. Epub 2013 Sep 2. Eur J Cancer. 2013. PMID: 24007819 Clinical Trial.
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Mirza MR, et al. N Engl J Med. 2016 Dec 1;375(22):2154-2164. doi: 10.1056/NEJMoa1611310. Epub 2016 Oct 7. N Engl J Med. 2016. PMID: 27717299 Free article. Clinical Trial.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Pujade-Lauraine E, et al. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Lancet Oncol. 2017. PMID: 28754483 Free article. Clinical Trial.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Poveda A, et al. Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18. Lancet Oncol. 2021. PMID: 33743851 Clinical Trial.
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG); Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO); Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO); National Cancer Research Institute (NCRI); Australia New Zealand Gynaecological Oncology Group (ANZGOG); Mario Negri Gynecologic Oncology group (MaNGO). Despierre E, et al. Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6. Target Oncol. 2015. PMID: 26004768 Free PMC article. Clinical Trial.
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Matulonis UA, Walder L, Nøttrup TJ, Bessette P, Mahner S, Gil-Martin M, Kalbacher E, Ledermann JA, Wenham RM, Woie K, Lau S, Marmé F, Casado Herraez A, Hardy-Bessard AC, Banerjee S, Lindahl G, Benigno B, Buscema J, Travers K, Guy H, Mirza MR. Matulonis UA, et al. Among authors: casado herraez a. J Clin Oncol. 2019 Dec 1;37(34):3183-3191. doi: 10.1200/JCO.19.00917. Epub 2019 Sep 16. J Clin Oncol. 2019. PMID: 31518175 Free PMC article.
Usefulness of Omalizumab in Rapid Drug Desensitization in Patients With Severe Anaphylaxis Induced by Carboplatin: Open Questions.
Sánchez-Morillas L, Casado Herráez A, Rubio-Perez M, Robledo Echarren T, González Gutiérrez ML, Cimarra M, Vázquez Cortés S, Cerecedo I, Fernández-Rivas M. Sánchez-Morillas L, et al. Among authors: casado herraez a. J Investig Allergol Clin Immunol. 2020;30(4):298-300. doi: 10.18176/jiaci.0499. Epub 2020 Feb 25. J Investig Allergol Clin Immunol. 2020. PMID: 32101175 Free article. No abstract available.
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orlowski R, Sachdev P, Shumaker R, Casado Herraez A. Makker V, et al. Among authors: casado herraez a. J Clin Oncol. 2020 Sep 10;38(26):2981-2992. doi: 10.1200/JCO.19.02627. Epub 2020 Mar 13. J Clin Oncol. 2020. PMID: 32167863 Free PMC article. Clinical Trial.
28 results